Teva Pharmaceutical Industries Ltd. ADR (TEVA)
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teva Pharmaceutical profit, revenue rise in fourth quarter
Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in fourth-quarter profit, boosted by sales of its branded drugs as well as a milestone payment to begin a late stage study to treat ulcerative colitis and Crohn's disease.
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teva Is No Longer A Turnaround Story, It's A Growth One
Teva Pharmaceutical (TEVA) remains a Buy, with specialty drugs, margin expansion, and the Royalty Pharma partnership driving further upside despite a 112% rally. TEVA's specialty pipeline—AUSTEDO, UZEDY, AJOVY—now anchors growth, with Royalty Pharma's $500M backing validating R&D and enabling non-dilutive financing. At under 12x 2026 earnings, TEVA trades below specialty pharma peers; a rerating to 14x could yield 19–30% further upside if execution continues.
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story
Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy. So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia
Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.
